Q2 2026 Dexcom Inc Earnings Call Transcript
Key Points
- DexCom Inc (DXCM) reported strong second-quarter 2026 revenue growth of 13% year-over-year, with international revenue growing 19%.
- The company's CONNECT trial for type 2 non-insulin patients showed a 0.9% A1c improvement over the control group, with 97% median CGM usage, strengthening the case for expanded reimbursement.
- Gross margin improved significantly to 64.1% in Q2 2026, up 400 basis points year-over-year, driven by manufacturing efficiencies and the G7 15-day system transition.
- DexCom Inc (DXCM) secured coverage for all people with diabetes across the four largest commercial PBMs, expanding access to over 7 million type 2 non-insulin patients.
- The company raised its full-year 2026 revenue guidance to $5.18-$5.25 billion and increased operating margin guidance to 23.5%-24%, reflecting strong execution and cost discipline.
- DexCom Inc (DXCM) was selected by the FDA for the Tempo digital device pilot, positioning the company to expand into prediabetes screening and metabolic health.
- The G7 15-day system is on track to convert nearly 50% of US customers by year-end, with improving Net Promoter Scores for three consecutive quarters.
- DexCom Inc (DXCM) generated over $600 million in free cash flow in the first half of 2026, more than double the prior year, and repurchased approximately $600 million in stock.
- DexCom Inc (DXCM) faces foreign exchange headwinds, with an expected $15 million impact on international revenue in the second half of 2026.
- The company's international growth faces tougher comparables in Q3 2026, which could moderate growth rates in the near term.
- DexCom Inc (DXCM) anticipates increased operating expenses in Q3 2026 due to hiring and training costs associated with the Ireland manufacturing facility launch.
- The CMS coverage decision for type 2 non-insulin patients is not expected until mid-2027, leaving a significant revenue opportunity delayed.
- International new patient starts declined sequentially in Q2 2026, partly due to tender timing, indicating potential volatility in OUS growth.
- The Nutrasense acquisition is expected to contribute minimal top-line revenue, with non-CGM revenue less than a few million dollars annually.
- DexCom Inc (DXCM) faces ongoing challenges in physician education and awareness regarding existing reimbursement coverage, which could slow adoption.
- The company's gross margin is expected to peak in Q3 2026 and then step down as the Ireland factory begins production, limiting near-term margin expansion.
Ladies and gentlemen, welcome to the DexCom second quarter 2026 earnings release conference call. My name is Abby, and I will be your operator for today's call. (Operator Instructions) As a reminder, the conference is being recorded.
I will now turn the call over to Sean Christensen, Senior Vice President of Finance and Investor Relations. Mr. Christensen, you may begin.
Thank you, operator, and welcome to DexCom's Second Quarter 2026 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and CEO, who will summarize our highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme Sylvain, our Chief Financial Officer.
Following our prepared remarks, we will open the call up for your questions. At that time, we ask analysts to limit themselves to one question each so we can provide an opportunity for everyone participating today. Please note that there are also slides available related to our second quarter 2026
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
